Video

VIDEO: Session reviews questions, controversies regarding initiation of ART in 2016

In this video, Rajesh Tim Gandhi, MD, of Massachusetts General Hospital, discusses his presentation at ASM Microbe on when to start ART, which focused on several areas.

The first focused on whether all patients with HIV should be treated. In particular, Gandhi discussed the role of the Strategic Timing of Antiretroviral Treatment trial and elite controllers. The second area examined whether all patients with HIV should be treated with an integrase inhibitor; the third posed the question of whether tenofovir alafenamide (TAF) should replace tenofovir disoproxil fumarate (TDF, Gilead Sciences).

Finally, he discussed the options available for patients with HIV who cannot take TAF, TDF or abacavir.

“Here, there are very few regimens that are available,” Gandhi said.

In this video, Rajesh Tim Gandhi, MD, of Massachusetts General Hospital, discusses his presentation at ASM Microbe on when to start ART, which focused on several areas.

The first focused on whether all patients with HIV should be treated. In particular, Gandhi discussed the role of the Strategic Timing of Antiretroviral Treatment trial and elite controllers. The second area examined whether all patients with HIV should be treated with an integrase inhibitor; the third posed the question of whether tenofovir alafenamide (TAF) should replace tenofovir disoproxil fumarate (TDF, Gilead Sciences).

Finally, he discussed the options available for patients with HIV who cannot take TAF, TDF or abacavir.

“Here, there are very few regimens that are available,” Gandhi said.

    See more from ASM Microbe